Irbesartan/Hydrocholorthiazide Teva (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is used within the antihypertensive drug class to manage high blood pressure.

• Primary hypertension: reduces systolic and diastolic pressure in patients with essential hypertension.
• Secondary hypertension: assists in controlling blood pressure when hypertension is caused by another underlying condition.
• Hypertensive urgency (as part of combination therapy): helps achieve target blood pressure when rapid reduction is needed under medical supervision.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, promoting sodium and water excretion. The combined actions lower peripheral vascular resistance and plasma volume, resulting in a sustained reduction of arterial blood pressure.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urinary frequency
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury or worsening renal function
• Hyperkalemia or severe hypokalemia
• Angioedema or severe allergic reaction
• Significant hypotension leading to syncope
• Hepatic dysfunction or jaundice

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate serum creatinine and eGFR prior to and during treatment.
• Electrolytes: check potassium and sodium levels regularly.
• Diabetes: monitor blood glucose as diuretics may affect glycemic control.
• Hepatic impairment: use with caution in patients with severe liver disease.
• Pregnancy and lactation: avoid unless clearly indicated by a physician.
• Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide may interact with several medicines; careful review is essential.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment
• Potassium‑sparing diuretics or supplements (risk of hyperkalemia)
• Lithium (increased lithium toxicity)
• ACE inhibitors or other ARBs (excessive hypotension, renal dysfunction)
• NSAIDs (reduced antihypertensive effect, renal risk)

Moderate Interactions (Monitor Closely)

• Other antihypertensives (additive blood pressure lowering)
• CYP2C9 inhibitors (e.g., fluconazole) may increase irbesartan levels
• Loop diuretics (enhanced diuretic effect, electrolyte loss)
• Antidiabetic agents (possible need for dose adjustment)